Contact

Titti Niskanen Square

Titti Niskanen

Director R&D and Clinical Operations

Send mail
News - 16 Mar 2021

Brand new publication on IBS

The probiotic strain, LP299V®, has been tried and trusted for more than 30 years. Available and used by consumers all over the world. Now, brand new clinical data has just been published.

This time, in a “real-life” study, with consumers having irritable bowel syndrome (IBS). These new findings are adding to the great amount of state-of-the-art clinical work already supporting the LP299V strain within the gastrointestinal health area.

The results are convincing, and the study showed a significant improvement for the consumers in daily IBS challenges such as abdominal pain, flatulence, diarrhea and constipation.

This clinical study on Probi’s proprietary strain Lactiplantibacillus plantarum 299v (LP299V®) was performed in Germany by our long-time partners Microbiotica. The study included more than 200 subjects with IBS. The participants were given a daily dose of 10 billion CFU of LP299V for 8-12 weeks and answered questions regarding their overall wellbeing and more precisely on severity and frequency of common IBS measures.

The results showed significant improvements in measures of IBS, including abdominal pain, flatulence, diarrhea and constipation. The essential quality of every-day life and mental wellbeing improved.

The brand-new evidence supporting this unique strain will be appreciated by both today’s and tomorrow’s consumers. Most importantly these convincing proofs show that the probiotic LP299V strain remains to be trusted.

This study was recently published in the leading German specialist journal Zeitschrift für Gastroenterologie, targeting gastroenterologists and other doctors interested in gastroenterology. The full study is written in German but abstract is available in English.

View abstract (in English): https://pubmed.ncbi.nlm.nih.gov/33556972/

 

This is provided for business-to-business communication and educational purposes only without warranties of any kind. Users should seek legal and/or regulatory advice prior to the market introduction of any Probi strain and before use of any claims to ensure compliance, due to different local laws and regulations.

Probi Probiotic Portfolio Web Banner 1500X625

Related content

A comprehensive portfolio to help your brand stand out. 

Probi combines a wide probiotic range with clinically proven strains and expertise, ensuring that our probiotics always perform...

Read more
Digestive Health - Page Header Banner 1500X625

Related information

Good health begins with gut health

The gut microbiota is highly diverse, hosting billions of bacteria, both harmful and beneficial. Maintaining balance between the...

Read more
Probi Clinical Study Web Banner 1500X625

Related information

Clinical studies library

Probi® has spent more than thirty years investigating the safety and efficacy of our probiotic strains. We conduct...

Read more